Exemestane + Entinostat for Advanced Breast Cancer

"As of now, there are 137 clinical trials involving Entinostat that are ongoing in 1914 cities and 61 countries. The very first trial began way back in 2000 and was completed when it reached Phase 3 drug approval stage in 2006. Since then, 339 more trials have been carried out."

"Entinostat's safety is estimated to be a 3. This conclusion comes from the fact that Entinostat is in Phase 3 of clinical trials. Having completed multiple rounds of testing with positive results, there is a significant amount of data supporting both the efficacy and safety of this medication."

"Unfortunately, this particular study is not looking for new patients right now. Although, it's worth noting that the last time this trial was edited was on October 18th, 2021. If you're interested in other studies, there are currently 5536 trials actively recruiting breast cancer patients and 137 clinical trials involving Entinostat that are still open to new participants."

"While often used as radiation therapy, Entinostat can also be prescribed to manage palliative care, endometrial thinning, and uterine hemorrhage."

"As of right now, this particular trial is not looking for any more patients. It was originally posted on March 29th, 2014 and has had its information edited as recently as October 18th, 2021. If you are interested in other trials, there are presently 5536 studies actively searching for patients with breast cancer and 137 trials for Entinostat that need participants."

"The primary outcome of this clinical trial, which will be evaluated over a Assessed at baseline, then every 12 weeks until treatment discontinuation, then every 3 months within 2 years from study entry, every 6 months between 2-5 years and annually between 6-10 years from study entry, until first disease progression time frame is to Progression-free survival (PFS). Secondary outcomes include Time-to-treatment Deterioration (TTD) which is defined as Time-to-treatment deterioration (TTD) was defined as time from randomization to disease progression or death or worsening of symptoms, whichever occurred first. Disease progression was"

"Currently, there are one hundred participating centres for this clinical trial. Some of these locations include Minnesota Oncology Hematology PA-Maplewood in Maplewood, Cleveland Clinic Akron General in Akron, and Delaware Radiation Oncology in Delaware."

"Entinostat was first explored in 2000 by Centre de Recherche Clinique du CHUS. As of now, 339 clinical trials have been completed while 137 are ongoing. The majority of active studies are taking place in Maplewood, Minnesota."